tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Idexx Laboratories sees FY23 comparable EPS up 19%-26%, consensus $9.50

Sees FY23 revenue $3.59B-$3.69B, consensus $3.62B. Sees FY23 free cash flow 80%-90% net income. Sees FY23 capital expenditures $180M.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on IDXX:

Disclaimer & DisclosureReport an Issue

1